Profile
Home  /   Staff  /   Researcher Profiles  /  Prof. John Forbes  /  Research Funding

Prof. John Forbes

Work Phone (02) 4985 0113
Fax (02) 4960 1539
Email
Office 2.041, Nbn Telethon Mater Institute

Funding

Summary

Number of grants 47
Total funding $27,730,067

For project grants received where the lead institution is other than the University of Newcastle, details are shown in italics.

Seeking students for this project. - Indicates that the researcher may be seeking students for this project.

Click on a grant title below to expand the full details for that specific grant.

2013 (4 grants)

Enabling Clinical Epigenetic Diagnostics: The Next Generation of Personalized Breast Cancer Care$605,301
Funding Body: National Breast Cancer Foundation

IBIS 3: Preventing late recurrence of ER positive breast cancer in postmenopausal women – a comprehensive approach$10,000
Funding Body: Hunter Medical Research Institute

IBIS 3: Preventing late recurrence of ER positive breast cancer in postmenopausal women – a comprehensive approach$10,000
Funding Body: University of Newcastle

2012 EIA Impact Trial travel grant$2,000
Funding Body: University of Newcastle

2012 (3 grants)

Maximising support for breast cancer research by the Australian Breast Cancer Tissue Bank.$70,000
Funding Body: National Breast Cancer Foundation

Medilink Array digitising system$35,000
Funding Body: NHMRC (National Health & Medical Research Council)

Longitudinal changes in mammographic density as a biomarker for future breast cancer events$24,360
Funding Body: Hunter Medical Research Institute

2011 (3 grants)

Hunter translational cancer research unit$1,693,333
Funding Body: Cancer Institute NSW

Targeting Breast Cancer Recurrence Through Epithelial Mesenchymal Plasticity$56,717
Funding Body: National Breast Cancer Foundation

p53 isoforms, a prognostic indicator in breast cancer?$45,000
Funding Body: Hunter Medical Research Institute

2010 (2 grants)

Mammographic density as a biomarker for the efficacy of treatment of endocrine therapies used to prevent breast cancer events in randomised controlled clinical trials$55,016
Funding Body: Cancer Institute NSW

The identification of microRNA's as therapeutic targets for the treatment of advanced breast cancer$21,600
Funding Body: Hunter Medical Research Institute

2009 (2 grants)

IBIS II: A randomised phase III trail of anastrozole for breast cancer prevention in postmenopausal women at high risk$1,635,000
Funding Body: NHMRC (National Health & Medical Research Council)

Provision of non-physical infrastructure support to enhance the breast cancer clinical trials research activities of the ANZ BCTG and its ability to build productive research collaborations$330,000
Funding Body: Cancer Institute NSW

2008 (5 grants)

Prevention of late breast cancer (BC) events in postmenopausal women with endocrine responsive BC$4,430,875
Funding Body: NHMRC (National Health & Medical Research Council)

Novel strategies for prediction and control of advanced breast cancer via nanoscaled epigenetic-based biosensors$1,200,000
Funding Body: National Breast Cancer Foundation

HMRI Cancer Research Program - MRSP Infrastructure$1,031,290
Funding Body: Hunter Medical Research Institute

Tailored treatments for premenopausal women with endocrine responsive breast cancer$287,000
Funding Body: NHMRC (National Health & Medical Research Council)

Support Funds for two clinical breast cancer trials: LATER and IBIS II$15,000
Funding Body: Hunter Medical Research Institute

2007 (2 grants)

Cognitive Function substudy for the SOFT trial$284,450
Funding Body: National Health & Medical Research Council

A clinical trial evaluating neoadjuvant chemotherapy for women with large operable or locally advanced breast cancer$259,500
Funding Body: NHMRC (National Health & Medical Research Council)

2006 (3 grants)

Follow-up of a randomised trial of Tamoxifen or placebo for breast cancer prevention in high risk women$861,143
Funding Body: NHMRC (National Health & Medical Research Council)

Infrastructure support for the ANZ BCTG clinical trials program$720,530
Funding Body: Cancer Australia

PRC - Priority Research Centre for Bioinformatics, Biomarker Discovery & Information-Based Medicine (CIBM)$621,143
Funding Body: University of Newcastle

2005 (5 grants)

Protocol development, web-based data collection and date quality assurance for all Cancer Cooperative Trials Groups$1,840,000
Funding Body: NHMRC (National Health & Medical Research Council)

Enhancement of the ANZBCTG research program through the provision of infrastructure funding for essential management and operational personnel and other key activities $1,720,564
Funding Body: Cancer Institute NSW

Tailored treatments for pre-menopausal patients with endocrine responsive breast cancer$253,314
Funding Body: NHMRC (National Health & Medical Research Council)

Follow-up of women on a randomised clinical trial of adjuvant docetaxel and doxorubicin for node positive breast cancer$111,750
Funding Body: NHMRC (National Health & Medical Research Council)

2005 RIBG allocation$65,000
Funding Body: University of Newcastle

2004 (2 grants)

NSW Tissue Bank$2,000,000
Funding Body: National Health & Medical Research Council

A randomised phase III trial of anastrozole for breast cancer prevention in postmenopausal women at high risk$1,566,000
Funding Body: NHMRC (National Health & Medical Research Council)

2002 (1 grants)

Follow-up phase of a randomised trial of Tamoxifen or placebo for breast cancer prevention in high risk women$450,000
Funding Body: NHMRC (National Health & Medical Research Council)

2001 (1 grants)

Randomised trials of adjuvant cytotoxic & endocrine therapy for early N+ and N- breast cancer.$510,095
Funding Body: NHMRC (National Health & Medical Research Council)

2000 (1 grants)

Clinical trial of adjuvant docetaxel and doxorubicin for node positive breast cancer.$182,187
Funding Body: NHMRC (National Health & Medical Research Council)

1998 (3 grants)

Randomised trial of tamoxifen or placebo for breast cancer prevention in high risk women$1,541,046
Funding Body: NHMRC (National Health & Medical Research Council)

Clinical trial of optimal chemotherapy in poor prognosis node positive early breast cancer$195,222
Funding Body: NHMRC (National Health & Medical Research Council)

Optimal endocrine and cytotoxic adjuvant therapy for node negative operable breast cancer$173,154
Funding Body: NHMRC (National Health & Medical Research Council)

1995 (4 grants)

95APP. Randomised trial of tamoxifen and placebo for breast cancer prevention in high risk women.$1,476,004
Funding Body: NHMRC (National Health & Medical Research Council)

Optimal endocrine and cytotoxic adjuvant therapy for node negative operable breast cancer.$348,825
Funding Body: NHMRC (National Health & Medical Research Council)

Surgical Oncology$35,000
Funding Body: Department of Education, Training & Youth Affairs

95APP. Applied biosystems 373 automated DNA sequencer and genotyper.$30,000
Funding Body: NHMRC (National Health & Medical Research Council)

1994 (1 grants)

Clinical trials of adjuvant chemo and hormone therapy in early breast cancer.$313,346
Funding Body: NHMRC (National Health & Medical Research Council)

1993 (1 grants)

93,94,95 GRANT. Randomised Trial of Local Treatment & Tamoxifen for In Situ Breast Cancer.$51,800
Funding Body: NHMRC (National Health & Medical Research Council)

1992 (1 grants)

Clinical trials for prevention and treatment of breast cancer.$293,410
Funding Body: NHMRC (National Health & Medical Research Council)

1991 (3 grants)

Clinical Trials Of Adjuvant Therapy In Node Positive Breast Cancer$199,859
Funding Body: NHMRC (National Health & Medical Research Council)

Adjuvant Therapy Trial For Node Negative Patients With Early Operable Breast Cancer$61,733
Funding Body: NHMRC (National Health & Medical Research Council)

Treatment Of Early Pre Invasive And Invasive Breast Cancer$7,500
Funding Body: Royal Australasian College of Surgeons